| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Styraxlignolide F targets multiple biological pathways including oxidative stress-responsive pathways and inflammatory signaling. The compound exhibits antioxidant activity through free radical scavenging mechanisms. Its anti-inflammatory effects are mediated through inhibition of pro-inflammatory cytokine production and modulation of NF-κB signaling. The compound may also exhibit anticancer activity through induction of apoptosis and inhibition of cell proliferation.
|
|---|---|
| ln Vitro |
In vitro, styraxlignolide F exhibits antioxidant activity through free radical scavenging. It demonstrates anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines. The compound may also show anti-cancer activity by inducing apoptosis in cancer cell lines. Its effects on cell signaling pathways have been characterized in cellular models, with modulation of inflammatory and oxidative stress pathways observed.
|
| ln Vivo |
In vivo studies on styraxlignolide F are limited. Based on its mechanism of action, the compound may have potential in inflammatory disorders and oxidative stress-related conditions. Its antioxidant and anti-inflammatory properties suggest potential in various disease models. Further in vivo studies are needed to fully characterize its pharmacological effects and therapeutic potential.
|
| Enzyme Assay |
For in vitro antioxidant assays, styraxlignolide F can be evaluated using DPPH or ABTS radical scavenging assays. The compound is incubated with radical solutions, and the decrease in absorbance is measured. Scavenging activity is calculated as a percentage. Anti-inflammatory activity can be assessed by measuring inhibition of pro-inflammatory cytokine production in stimulated cells using ELISA.
|
| Cell Assay |
For in vitro cell-based assays, styraxlignolide F is typically tested on immune cells or cancer cell lines. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cytokine production is measured by ELISA. Apoptosis is evaluated by flow cytometry. Signaling pathway modulation is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for styraxlignolide F have not been extensively reported. Based on its anti-inflammatory and antioxidant activities, potential experimental models include inflammation models in mice or rats. The compound could be administered orally or intraperitoneally, with inflammatory markers assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for styraxlignolide F are limited. As a lignan glycoside, it is expected to have moderate oral bioavailability. The glycoside moiety may be hydrolyzed in the gastrointestinal tract. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for styraxlignolide F are limited. As a natural product isolate, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
According to reports, benzoin (Styrax japonicus) contains benzoin lactone F, and relevant data is available for reference.
Styraxlignolide F is a research-use only compound and has not been approved for clinical applications. It is a lignan glycoside natural product. Its molecular weight and formula are well-characterized. It is available from various research chemical suppliers. Further research is needed to fully elucidate its pharmacological profile and therapeutic potential. |
| Molecular Formula |
C27H34O11
|
|---|---|
| Molecular Weight |
534.5523
|
| Exact Mass |
534.21
|
| CAS # |
823214-06-8
|
| PubChem CID |
11330069
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
756.4±60.0 °C at 760 mmHg
|
| Melting Point |
128-130 °C
|
| Flash Point |
250.1±26.4 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| Source |
Originated from plants: other families
|
| LogP |
0.23
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
38
|
| Complexity |
753
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C(C1C=CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)=C(OC)C=1)[C@@H]1COC(=O)[C@H]1CC1C=CC(OC)=C(OC)C=1
|
| InChi Key |
AEMJDNJKSCBKRL-ZYKRCLGOSA-N
|
| InChi Code |
InChI=1S/C27H34O11/c1-33-18-6-4-15(11-20(18)34-2)9-17-16(13-36-26(17)32)8-14-5-7-19(21(10-14)35-3)37-27-25(31)24(30)23(29)22(12-28)38-27/h4-7,10-11,16-17,22-25,27-31H,8-9,12-13H2,1-3H3/t16-,17+,22-,23-,24+,25-,27-/m1/s1
|
| Chemical Name |
(3S,4S)-3-[(3,4-dimethoxyphenyl)methyl]-4-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~187.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8707 mL | 9.3537 mL | 18.7073 mL | |
| 5 mM | 0.3741 mL | 1.8707 mL | 3.7415 mL | |
| 10 mM | 0.1871 mL | 0.9354 mL | 1.8707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
